Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Aug;8(8):1063-70.
doi: 10.1517/14712598.8.8.1063.

Biofunctionalized targeted nanoparticles for therapeutic applications

Andrew Z Wang  1 , Frank Gu, Liangfang Zhang, Juliana M Chan, Aleksander Radovic-Moreno, Mariam R Shaikh, Omid C Farokhzad
Affiliations
Review

Biofunctionalized targeted nanoparticles for therapeutic applications

Andrew Z Wang et al. Expert Opin Biol Ther. 2008 Aug.

Abstract

Background: The development of nanoparticles for the delivery of therapeutic agents has introduced new opportunities for the improvement of medical treatment. Recent efforts have focused on developing targeted nanoparticles, which are formulated by (for therapeutic delivery) functionalizing nanoparticle surfaces with targeting molecules, such as antibodies, peptides, small molecules and oligonucleotides.

Objectives: To review the state of targeted nanoparticles development.

Methods: The authors discuss the nanoparticle platforms for therapeutic delivery, targeting molecules and the biofunctionalized targeted nanoparticles currently in development.

Results/conclusions: Biofunctionalized targeted nanoparticles have demonstrated exciting results in preclinical studies. With continued improvements, they may fulfill their potential as therapeutics carriers that can deliver the maximum dose to diseased tissue while minimizing effects on normal cells.

PubMed Disclaimer

Conflict of interest statement

DECLARATION OF INTEREST: The authors received support from National Institutes of Health Grants CA119349 and EB003647 and Koch–Prostate Cancer Foundation Award in Nanotherapeutics. The authors declare no conflicts of interest.

References

    1. Wagner V, Dullaart A, Bock A-K, Zweck A. The emerging nanomedicine landscape. Nat Biotech. 2006;24:1211–7. Excellent review of the nanomedicine industry. - PubMed
    1. Emerich DF, Thanos CG. Targeted nanoparticle-based drug delivery and diagnosis. J Drug Target. 2007 Apr;15(3):163–83. - PubMed
    1. Groneberg DA, Giersig M, Welte T, Pison U. Nanoparticle-based diagnosis and therapy. Curr Drug Targets. 2006 Jun;7(6):643–8. - PubMed
    1. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002 Jan 1;94(1):25–36. - PubMed
    1. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol. 1995 Jul;13(7):1777–85. Demonstrated liposomal doxorubicin has lower toxicity profile when compared to doxorubicin. - PubMed

Publication types

LinkOut - more resources